A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice

In this study, we investigated whether plasmid containing Sema3a could ameliorate bone loss in an ovariectomized (OVX) mouse model via (AspSerSer)6, a selectively bone-targeting moiety. Plasmid pcDNA3.1(+)-Sema3a-GFP was fabricated and transfected cells with the plasmid demonstrated statistically higher levels of Sema3A in vitro (p  

https://www.thebonejournal.com/article/S8756-3282(18)30231-X/fulltext?rss=yes

Source: Bone - June 5, 2018 Category: Orthopaedics Authors: K. Yang, R.J. Miron, Z. Bian, Y.F. Zhang Tags: Full Length Article Source Type: research